Duluth, GA, August 12, 2026 (Yahoo Finance) -- Bridge Life Sciences has raised $110 million in new financing to support the advancement of its therapeutic pipeline. The company plans to use the capital to accelerate development programs and strengthen its research and clinical capabilities. The financing provides additional resources to support the company’s growth and progress toward future clinical milestones. Read full article here.

Menlo Park, CA, August 5, 2026 (PacBio) -- Pacific Biosciences of California has appointed Mark Van Oene as president and chief executive officer, effective August 17, 2026. Van Oene brings extensive experience in the life sciences and genomics industry and will lead the company as it focuses on expanding adoption of its sequencing technologies. The leadership change is expected to support PacBio’s commercial growth and continued development of its long-read sequencing plat

Irvine, CA, August 6, 2026 (Reuters) -- Tarsus Pharmaceuticals has agreed to acquire Alkeus Pharmaceuticals in a transaction valued at up to $800 million. The deal gives Tarsus access to an investigational therapy targeting Stargardt disease, an inherited retinal disorder with no approved treatment. The acquisition broadens Tarsus’ ophthalmology pipeline and supports its strategy of developing therapies for underserved eye diseases. Read full article here.

Santa Cruz, CA, August 11, 2026 (Business Wire) -- Versa Vascular has appointed Bill Shields as chief executive officer, bringing an experienced medical technology executive to lead the company’s next stage of growth. Shields will focus on advancing the company’s vascular technology platform and expanding its commercial reach. His appointment is expected to support broader adoption of Versa Vascular’s solutions and strengthen the company’s position in the vascular device ma

Dublin, Ireland, August 10, 2026 (Yahoo Finance) -- Jazz Pharmaceuticals has agreed to acquire privately held Actio Biosciences in a transaction valued at up to $1.32 billion. The deal adds ABS-1230, an investigational therapy being developed for KCNT1-related epilepsy, a rare inherited disorder that can cause severe seizures and developmental complications in children. The acquisition expands Jazz’s neuroscience portfolio and strengthens its focus on developing treatments

Waltham, MA, July 22, 2026 (Reuters) -- Repligen has agreed to acquire BioLife Solutions in a transaction valued at approximately $1.5 billion. The acquisition expands Repligen’s portfolio of bioprocessing technologies and strengthens its capabilities in supporting cell and gene therapy manufacturing. The deal is expected to enhance the company’s offerings for biopharmaceutical customers and support its long-term growth strategy. Read full article here.

Indianapolis, IN, July 20, 2026 (PR Newswire) -- Roche Diagnostics North America has appointed Dan Malarek as president and chief executive officer. Malarek will lead the company’s North American diagnostics business, overseeing commercial strategy, operations, and continued innovation across its portfolio. The leadership appointment is intended to strengthen Roche’s position in the region and support future growth in diagnostic solutions. Read full article here.

Tempe, AZ, June 9, 2026 (PR Newswire) -- GT Medical Technologies has completed an oversubscribed $100 million Series E equity financing to support commercialization of its treatment for patients with operable brain tumors. The proceeds will be used to expand market adoption, scale manufacturing, and advance additional clinical and commercial initiatives. The financing strengthens the company's position as it broadens access to its targeted radiation therapy platform. Read f

Cambridge, MA, July 27, 2026 (Business Wire) -- Sarepta Therapeutics has appointed Michael F. Severino as chief executive officer. Severino will lead the company’s strategic direction as it advances its portfolio of genetic medicines and commercial operations. The leadership appointment is intended to strengthen execution across Sarepta’s pipeline and support its next phase of growth. Read full article here.

Indianapolis and New York, July 16, 2026 (PR Newswire) -- Eli Lilly and Company has agreed to acquire Atai Beckley in a deal worth up to $1.6 billion. The acquisition is intended to strengthen Lilly’s pipeline of therapies for treatment-resistant depression and other mental health disorders by adding novel neuropsychiatric programs. The transaction supports Lilly’s strategy to expand its neuroscience portfolio with innovative treatments for patients with significant unmet n

Stockholm, Sweden, July 7, 2026 (EQT) -- EQT has agreed to acquire the TachoSil biosurgery business from Corza Medical. The transaction will establish TachoSil as an independent company focused on advancing its surgical sealant portfolio and expanding its global market presence. EQT plans to support the business through continued investment in commercial growth, product innovation, and strategic expansion. Read full article here.

San Diego, CA, July 7, 2026 (Globe Newswire) -- ARS Pharmaceuticals has announced a CEO succession plan, with Richard Lowenthal assuming the role of chief executive officer. The leadership transition is designed to support the company’s continued commercial growth and strategic priorities. ARS Pharmaceuticals expects the change to provide continuity as it advances its product portfolio and long-term expansion plans. Read full article here.